Celator Investor Looks To Block $1.5B Jazz Pharma Deal
A Celator investor asked a New Jersey federal court Monday to halt the oncology biotech's planned $1.5 billion sale to Jazz Pharmaceuticals, contending the too-low deal is the result of a...To view the full article, register now.
Already a subscriber? Click here to view full article